Evidence map›Paper›PMID 40251535›Full record

ArticleBMC infectious diseases2025

Risk factors for mortality among kidney transplant recipients with COVID-19 in Saudi Arabia: a case-control study.

Dema A Alissa, Rawan Almasuood, Baraa Alghalyini, Hala Tamim, Mohammed Alaa Raslan, Abdul Rehman Zia Zaidi, Bader Abou Shaar, Mhd Malek Al Masri, Adnan Abdul Karim, Wejdan Aburas and 3 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dema A AlissaTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia. daalissa@gmail.com.
Rawan AlmasuoodTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Baraa AlghalyiniDepartment of Family and Community Medicine, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Hala TamimDepartment of Family and Community Medicine, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Mohammed Alaa RaslanColleges of Medicine and Pharmacy, Al-Faisal University, Riyadh, Saudi Arabia.
Abdul Rehman Zia ZaidiDepartment of Family and Community Medicine, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Bader Abou ShaarDepartment of Family and Community Medicine, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Mhd Malek Al MasriColleges of Medicine and Pharmacy, Al-Faisal University, Riyadh, Saudi Arabia.
Adnan Abdul KarimColleges of Medicine and Pharmacy, Al-Faisal University, Riyadh, Saudi Arabia.
Wejdan AburasTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Waled AburasCollege of Pharmacy, University of Hail, Hail, Saudi Arabia.
Ahmed H Al-JedaiTherapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Reem S AlmaghrabiOrgan Transplant Centre of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has profoundly impacted global health, leading to over 74 million confirmed cases and 1.67 million deaths by December 2020. In Saudi Arabia, extensive measures were implemented to mitigate the spread of the virus. Kidney transplant recipients, due to their immunosuppressed status, are particularly vulnerable to severe COVID-19 outcomes. This study aims to identify risk factors associated with mortality in COVID-19-infected kidney transplant patients in Saudi Arabia. The primary objective is to identify mortality risk factors among COVID-19-infected kidney transplant patients. The secondary objective is to compare clinical management and outcomes between deceased and recovered patients. METHODOLOGY: This case-control study matched 82 deceased kidney transplant patients (cases) with 151 survivors (controls). Data were collected from the National Registry for COVID-19 Mortality and King Faisal Specialist Hospital and Research Centre (KFSH&RC) for patients diagnosed between March 2020 and January 2021. Key variables included demographic information, comorbidities, clinical symptoms, and treatment details. Statistical analyses involved chi-square tests and multivariable logistic regression to assess associations with mortality.

resultsAmong cases, 93.9% required ICU admission, and 95.1% were intubated. Males constituted 73.2% of cases, with 53.7% aged over 60. Cardiovascular comorbidities were more prevalent among cases (97% vs. 87.4%, p = 0.01). and presented more frequently with fever, cough, and respiratory distress. In multivariable analysis, fever, shortness of breath, and desaturation were associated with increased mortality odds. Notably, patients who discontinued immunosuppressive therapy had higher mortality odds (OR = 63.2, p = 0.083), whereas those who held or adjusted their therapy had significantly lower odds (OR = 0.1, p = 0.042; OR = 0.0, p = 0.007). Bacterial infections also increased mortality risk (OR = 56.6, p = 0.009).

conclusionThis study identifies critical risk factors for mortality among kidney transplant patients infected with COVID-19 in Saudi Arabia. The findings underscore the need for tailored clinical management strategies to improve outcomes in this vulnerable population. Further research is warranted to explore long-term implications and effective treatment protocols.

Indexed as

COVID-19Kidney TransplantationTransplant RecipientsAdultAgedCase-Control StudiesComorbidityFemaleHumansMaleMiddle AgedRisk FactorsSARS-CoV-2Saudi ArabiaCOVID-19Kidney transplant recipientsMortalityRisk factorsSaudi Arabia

Identifiers

PMID40251535
PMCPMC12008917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.